Update on cystic fibrosis-related diabetes

被引：137

作者：

Kelly, Andrea ^{[1
]}

Moran, Antoinette ^{[2
]}

机构：

[1] Univ Penn, Childrens Hosp Philadelphia, Div Endocrinol & Diabet, Perelman Sch Med, Room 1559,3535 Market St, Philadelphia, PA 19104 USA

[2] Univ Minnesota, Minneapolis, MN 55455 USA

来源：

JOURNAL OF CYSTIC FIBROSIS | 2013年 / 12卷 / 04期

关键词：

Cystic fibrosis; Diabetes; Hyperglycemia; Cystic fibrosis-related diabetes; TRANSMEMBRANE CONDUCTANCE REGULATOR; GASTRIC-INHIBITORY POLYPEPTIDE; SUBCUTANEOUS INSULIN INFUSION; IMPAIRED FASTING GLUCOSE; PEPTIDE-1; 7-36; AMIDE; BETA-CELL APOPTOSIS; ENDOCRINE PANCREAS; CLINICAL STATUS; LUNG-FUNCTION; ORAL GLUCOSE;

D O I：

10.1016/j.jcf.2013.02.008

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Diabetes mellitus has emerged as a common comorbidity in cystic fibrosis and is considered a clinical entity (cystic fibrosis-related diabetes, CFRD) distinct from that of type 1 diabetes (T1DM) and type 2 diabetes (T2DM). The relevance of this diagnosis extends not only from its imposition of additional medical burden but its association with worse health outcomes in individuals with CF. This paper will review the 2010 U.S. and other international guidelines for screening and treating CFRD. It will highlight newer data regarding early glucose and insulin secretion defects, mechanisms linking CFRD to worse outcomes, and recent advances in T2DM that may provide insights for CFRD; insulin secretion will be reviewed as background for these recent developments. (c) 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

引用

页码：318 / 331

页数：14

共 112 条

[1] Two-Step Approach for the Prediction of Future Type 2 Diabetes Risk [J].

Abdul-Ghani, Muhammad A. ;

Abdul-Ghani, Tamam ;

Stern, Michael P. ;

Karavic, Jasmina ;

Tuomi, Tiinamaija ;

Bo, Insoma ;

DeFronzo, Ralph A. ;

Groop, Leif .

DIABETES CARE, 2011, 34 (09) :2108-2112

[2]

ABDULKARIM FW, 1986, ARCH PATHOL LAB MED, V110, P602

[3]

Amer Diabet Assoc, 2012, DIABETES CARE, V35, pS64, DOI [10.2337/dc19-S002, 10.2337/dc12-S064, 10.2337/dc23-S002, 10.2337/dc09-S062, 10.2337/dc18-S002]

[4] Cystic fibrosis-related diabetes - The presence of microvascular diabetes complications [J].